Over 40 Yale Cancer Center (YCC) physicians and scientists will present new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. This is the largest and most attended conference for oncology professionals, who are interested in learning about the latest, practice-changing cancer research.

This year's ASCO meeting features over 200 oral, poster, and educational sessions complementing the meeting theme, “Driving Knowledge to Action: Building a Better Future.” YCC researchers will share advances for new therapies with research areas covering breast, lung, prostate, head and neck, early onset, and metastatic cancers. Director of YCC’s clinical trials office and YCC’s chief clinical research officer, Ian Krop, MD, PhD, will also receive the Gianni Bonadonna Breast Cancer Award during a special ASCO session on May 31.

YCC Presentations:

Friday, May 30

Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients with ER+/HER2− metastatic breast cancer: Results from phase 1 study to support the recommended phase 3 dose (RP3D)

Presenter: Pat LoRusso, DO

Saturday, May 31

Redefining the Role of Chemotherapy in the Era of Targeted Therapies in Breast Cancer

Chair and Moderator: Eric Winer, MD

Award Recipient and Speaker: Dr. Ian Krop

Sunday, June 1

Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas

Presenter: Curtis Perry, MD, PhD

Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy

Presenter: Lajos Pusztai, MD

Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial

Presenter: Renee Saliby

Highlights of the Day I: Head and Neck Cancer

Presenter: Barbara Burtness, MD

Monday, June 2

Prospective decision impact study of the Breast Cancer Index: Results from the BCI Registry study

Presenter: Tara Sanft, MD

Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC)

Presenter: David Braun, MD, PhD

Phase 2 results of an all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy

Presenter: Amer Zeidan, MBBS

For media members interested in scheduling expert interviews, contact michael.masciadrelli@yale.edu.

About Yale Cancer Center:

Yale Cancer Center combines a tradition of innovative cancer treatment and quality care for our patients. A National Cancer Institute (NCI) designated comprehensive cancer center since 1974, Yale Cancer Center is one of only 57 such centers in the nation and the only one in Connecticut. Yale Cancer Center members include national and internationally renowned scientists and physicians at Yale School of Medicine and Smilow Cancer Hospital. This partnership enables the Center to provide the best approaches for prevention, detection, diagnosis, and treatment for cancer.